References
1. Tufts Center for the Study of Drug Development Press Release: Biotech Products in Big Pharma Clinical Pipelines Have Grown Dramatically. November 14, 2013. Available at: csdd.tufts.edu/news/complete_story/pr_ir_nov_dec_2013. Accessed July 19, 2015.
2. Connelly D. (2014) Clin Pharm. Sept. Available at: http://www.pharmaceutical-journal.com/publications/previous-issues/cp-september-2014/a-history-of-aspirin/20066661.article. Accessed July 19, 2015.
3. Lipinski C.A. (2004) Drug Discov Today Technol. Dec 1(4):337-341.
4. Veber D.F., et al. (2002) J Med Chem.45:2615-2623; Lipinski C.A. (2004) Drug Discov Today Technol. Dec 1(4):337-341.
5. Kelder J., et al. (1999) Pharm Res. 16:1514-1519; Lipinski C.A. (2004) Drug Discov Today Technol. Dec 1(4):337-341.
6. Norinder U., et al. (2002) Adv. Drug Deliv Rev. 54:291-313.
7. Eggert US. (2013) Nature Chemical Biology. 9:206-209.
8. Eggert US. (2013) Nature Chemical Biology. 9:206-209.
9. Eggert US. (2013) Nature Chemical Biology. 9:206-209.
10. http://www.mayoclinic.org/drugs-supplements/colchicine-oral-route/description/drg-20067653
11. Eggert US. (2013) Nature Chemical Biology. 9:206-209.
12. National Cancer Institute. Targeted Therapies Fact Sheet. http://www.cancer.gov/about-cancer/treatment/types/targeted-therapies/targeted-therapies-fact-sheet
13. Batashaw M.L., et al. (2001) J Pediatr. 138:S46-54.
14. Melichar B., et al. (1998) Clin Cancer Res. 4:3069-3076.
15. Leiro J., et al. (2005) Int Immunopharm. 5(2):393-406.
16. Hoelder S., et al. (2012) Mol Oncol. 6:155-176.
17. Schellekens H. (2009) NDT Plus. 2(suppl 1):i27-i36.
18. Schellekens H. (2009) NDT Plus. 2(suppl 1):i27-i36.
19. Schellekens H. (2009) NDT Plus. 2(suppl 1):i27-i36.
20. Schellekens H. (2009) NDT Plus. 2(suppl 1):i27-i36.
21. Smith SW. Toxicol Sci. 2009;110(1):4-30.
22. Smith SW. Toxicol Sci. 2009;110(1):4-30.
23. Smith SW. Toxicol Sci. 2009;110(1):4-30.
24. Smith SW. Toxicol Sci. 2009;110(1):4-30.
25. Hughes JP, Rees S, Kalindjian SB, Philpott KI (2011) Br J Pharmacol. 162: 1239-1249
26. http://csdd.tufts.edu/files/uploads/Tufts_CSDD_briefing_on_RD_cost_study_-_Nov_18,_2014.pdf
27. http://csdd.tufts.edu/files/uploads/Tufts_CSDD_briefing_on_RD_cost_study_-_Nov_18,_2014.pdf
28. Paul SM, Mytelka DS, Dunwiddie CT, et.al. (2010) Nat RevDrug Discov 9: 203-214.
29. Paul SM, Mytelka DS, Dunwiddie CT, et.al. (2010) Nat RevDrug Discov 9: 203-214.
30. Paul SM, Mytelka DS, Dunwiddie CT, et.al. (2010) Nat RevDrug Discov 9: 203-214.
31. Paul SM, Mytelka DS, Dunwiddie CT, et.al. (2010) Nat RevDrug Discov 9: 203-214.
32. https://explorable.com/scientific-control-group
33. Hughes JP, Rees S, Kalindjian SB, Philpott KI (2011) Br J Pharmacol. 162: 1239-1249
34. Lentz TL, Hilleman DE (2000) Pharmacotherapy. 20(7): 776-786
35. Lynch JJ Jr, Wallace AA, Stupienski RF 3rd, et.al. (1994) J Pharmacol Exp Ther. 269(2): 541-554
36. Gerlach AC, Stoehr SJ, Castle NA (2010) Mol Pharmacol. 77(1): 56-68
37. Walsh KB, (2015) Expert Opin Drug Discovery. 10(2): 157-159
38. Thomas D, Karle CA, Kiehn J (2006) Curr Pharm Des. 12(18): 2271-2283
39. Hughes JP, Rees S, Kalindjian SB, Philpott KI (2011) Br J Pharmacol. 162: 1239-1249
40. Macarron R, Banks MN, Bojanic D, et.al. (2011) Nat Rev Drug Discov. 10: 188-195
41. Biology, chemistry, in vitro and in vivo pharmacology, drug metabolism, formulations and safety assessment.
42. Hughes JP, Rees S, Kalindjian SB, Philpott KI (2011) Br J Pharmacol. 162: 1239-1249
43. Hughes JP, Rees S, Kalindjian SB, Philpott KI (2011) Br J Pharmacol. 162: 1239-1249
44. https://www.nlm.nih.gov/services/ctphases.html
45. https://regulatory.usc.edu/consulting/resources/drugs/fda-filing/
46. Hoelder S, Clarke PA, Workman P (2012) Molecular Oncology 6: 155-176
47. https://explorable.com/scientific-control-group
48. https://explorable.com/scientific-control-group
49. Huang ME, Yem YC, Chen SR, et. al. (1998) Blood 72: 567-572
50. O’brien SG, Guilhot F, Larson RA, et.al.(2003) N Engl J Med. 348: 994-1004 Druker BJ, Guilhot F, O’Brien SG, et.al.(2006) N Engl J Med. 355: 2408-2417
51. Yap TA, Workman P, (2012) Ann Rev Pharmacol Toxicol. 52: 549-573
52. Yap TA, Workman P, (2012) Ann Rev Pharmacol Toxicol. 52: 549-573
53. Yap TA, Workman P, (2012) Ann Rev Pharmacol Toxicol. 52: 549-573
54. de Bono, JS, Logothetis, CJ, Molina, A, et.al. (2011) N Engl J Med. 364: 1995-2005
55. Kwak EL, Bang Y-J, Camidge DR, et.al. (2010) N Engl J Med. 363: 1693-1703
56. Chapman PB, Hauschild A, Robert C, et.al. (2011) N Engl J Med. 364: 2507-2516
57. http://dnp.chemnetbase.com/intro/DNPIntroduction.pdf
58. Stone E (1763) Phil Trans Royal Soc. London 53: 195-200
59. www.rxlist.com/vancomycin-injection-drug.htm
60. www.nim.nih.gov/medlineplus/druginfo/meds/a604038.html
61. Bourinbaiar, AS, Coleman CF (1997) Arch Virol. 142: 225-2235
62. Greinacher A, Warkentin TE (2008) Thromb Haemost. 99(5):819-29
63. http://www.rxlist.com/heparin-drug.htm
64. Hirsh J, Anand SS, Halperin JL et.al. (2001) Arterioscler Thromb Vasc Biol. 21:1094-1096
65. Ji, H-F, Li X-J, Zhang H-Y 2009 EMBO Rep. 10(3): 194-200
66. Cragg GM, Newman DJ (2013) Biochim Biophys Acta 1830(6) 3670-3695
67. Newman DJ, Cragg GM (2012) J Nat Prod. 75(3) 311-335
68. Ganem B, Franke RR (2007) J Org Chem. 72(11) 3981-3987
69. Nicolaou, KC (2014) Proc Math Phys Eng. Sci. 470(March 8) 2163
70. Khani S, Barar J, Movafeghi A et.al. (2012) Biotechnological Production of Plant Secondary Metabolites: Bentham Books, Orhan IE editor p.215-240
71. Bringmann G, Gulder TAM, Lang G (2007) Mar Drugs 5(2) 23-30
72. “What are “Biologics” Questions and Answers http://www.fda.gov/AboutFDA/CentersOffices/OfficeofMedicalProductsandTobacco/CBER/ucm133077.htm
73. Demain AL, Vaishnav P (2011) Microbial Biotech. 4(6) 687-699
74. Gleevec (imatinib mesylate) Questions and Answers http://www.fda.gov/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/ucm110505.htm
75. Dovitinib lactate http://www.cancer.gov/publications/dictionaries/cancer-drug?cdrid=488976
76. “Utilization and cost of anticancer biologic products among Medicare beneficiaries, 2006-2009” http://www.effectivehealthcare.ahrq.gov/ehc/products/345/768/DataPoints6.pdf
77. Dolan DE, Gupta S (2014) Cancer Control. 21(3) 231-7
78. Prisinzano TE (2009) J Nat Prod. 72(3) 581-587
79. Alewijnse AE, Smit MJ, Rodriguez Pena MS et. al. (1997) FEBS Lett. 419(2-3) 171-174
80. Muszynska B, Lojewski M, Rojowski J et.al. (2015) Psychiatr Pol. 49(3) 435-453
81. “Characterizing Markets for Biopharmaceutical Innovations: Do Biologics differ from small molecules?” Trusheim MR, Aitken ML, Berndt ER (2010) http://hdl.handle.net/1721.1/62181
82. “Characterizing Markets for Biopharmaceutical Innovations: Do Biologics differ from small molecules?” Trusheim MR, Aitken ML, Berndt ER (2010) http://hdl.handle.net/1721.1/62181
83. Source: Drugs.com Statistics, 2012 “US pharmaceutical sales – 2012” source: IMS Health (Midas) http://www.drugs.com/stats/top100/2012/sales
84. http://www.ispe.org/gmp-resources
85. http://cen.acs.org/articles/93/web/2015/08/US-Food-Drug-Administration-Approves.html
86. http://cen.acs.org/articles/93/i45/Roche-Sheds-Small-Molecule-Manufacturing.html
87. http://healthaffairs.org/blog/2015/10/16/who-makes-this-drug-disclosing-the-identity-of-generic-drug-manufacturers/
88. http://cen.acs.org/articles/92/i9/Lab-Production-Plant.html
89. http://cen.acs.org/articles/92/i39/Chemistry-Rises-Top-Contract-Manufacturers.html
90. http://cen.acs.org/articles/92/i39/Chemistry-Rises-Top-Contract-Manufacturers.html
91. Cipolla L. Comb Chem High Throughput Screen. 2004 Mar;7(2):101-14.
92. Arnold FH. Nature (2001) 409, 253-257.
93. http://research.chem.psu.edu/mallouk/articles/203025_o.pdf
94. http://cen.acs.org/articles/91/i44/Still-Waiting-Times.html
95. http://cen.acs.org/articles/91/i21/Europeans-Seek-Competitive-Advantage-Continuous.html
96. http://cen.acs.org/articles/92/i39/Chemistry-Rises-Top-Contract-Manufacturers.html
97. http://cen.acs.org/articles/92/i39/Chemistry-Rises-Top-Contract-Manufacturers.html
98. Moran, Sean (2015). An Applied Guide to Process and Plant Design (1st ed.). Butterworth-Heinemann. ISBN 0128002425.
99. http://healthaffairs.org/blog/2015/10/16/who-makes-this-drug-disclosing-the-identity-of-generic-drug-manufacturers/
100. http://cen.acs.org/articles/92/i8/FDA-Head-Voices-Concerns-India.html
101. http://www.fda.gov/Drugs/DevelopmentApprovalProcess/HowDrugsareDevelopedandApproved/ApprovalApplications/AbbreviatedNewDrugApplicationANDAGenerics/
102. http://www.nytimes.com/2013/09/23/booming/the-death-and-afterlife-of-thalidomide.html accessed Dec 30, 2015.
103. http://www.nytimes.com/2013/09/23/booming/the-death-and-afterlife-of-thalidomide.html?_r=1
104. http://staging.nxtbook.com/ygsreprints/FDLI/g37642_fdli_novdec2013/stage.php#/30
105. http://staging.nxtbook.com/ygsreprints/FDLI/g37642_fdli_novdec2013/stage.php#/30
106. http://staging.nxtbook.com/ygsreprints/FDLI/g37642_fdli_novdec2013/stage.php#/30
107. http://staging.nxtbook.com/ygsreprints/FDLI/g37642_fdli_novdec2013/stage.php#/30
108. http://www.nytimes.com/2015/08/08/science/frances-oldham-kelsey-fda-doctor-who-exposed-danger-of-thalidomide-dies-at-101.html
109. https://embryo.asu.edu/pages/us-regulatory-response-thalidomide-1950-2000
110. https://embryo.asu.edu/pages/us-regulatory-response-thalidomide-1950-2000
111. http://www.thalomid.com/. Prescribing Information.
112. http://www.thalomid.com/. Prescribing Information.
113. Mayo Clinic Diseases and Conditions. Depression (major depressive disorder) June 21, 2013. http://www.mayoclinic.org/diseases-conditions/depression/in-depth/maois/art-20043992
114. Carradori S, Silvestri R. J. Med.Chem. 2015;58(17):6717-6732.
115. http://www.alz.org/research/science/major_milestones_in_alzheimers.asp
116. http://www.alz.org/research/science/major_milestones_in_alzheimers.asp
117. http://www.alz.org/research/science/alzheimers_disease_treatments.asp#approved
118. Gosh, AK, Osswald HL. Chem Soc. Rev. 2014;43(19):6765-6813.
119. http://www.cen.acs.org/articles/93/web/2015/12/Chemist-Explains-Piece-together-possible.html
120. Menting KW, Claassen JA. Front. Aging Neurosci. 2014; 6, 165.
121. Wyss DF, Wang YS, Eaton HL, et.al. Top. Curr. Chem. 2012;317:83-114.
122. Kuzirian AM, Epstein HT, Gagliardi CJ, et.al. Biol. Bull. 2006; 210(3):201-214.
123. Myeku N, Clelland CL, Emrani S, et.al. Nat Med. 2016; 22(1):46-53.
124. Cuadrado-Tejedor M, Hercias I, Ricobaraza A, et.al. Br J Pharmacol. 2011;164(8):2029-2041.
125. Garcia-Osta A, Cuadrado-Tejedor M, Garcia-Barroso C, et.al. ACS Chem Neurosci. 2012; 3(11):832-844.
126. www.alzforum.org/news/research-news/et-tu-methylene-blue-drug-only-works-prophylactic
127. www.alzforum.org/therapeutics/elnd005
128. Goetz CG. Cold Spring Harb Perspect Med. 2011;1:a008862.
129. Goetz CG. Cold Spring Harb Perspect Med. 2011;1:a008862.
130. Goetz CG. Cold Spring Harb Perspect Med. 2011;1:a008862.
131. Franciscus A. A Brief History of Hepatitis C. HCSP Fact Sheet. March 2015. http://hcvadvocate.org/hepatitis/factsheets_pdf/Brief_History_HCV.pdf. Accessed February 16, 2016.
132. Franciscus A. A Brief History of Hepatitis C. HCSP Fact Sheet. March 2015. http://hcvadvocate.org/hepatitis/factsheets_pdf/Brief_History_HCV.pdf. Accessed February 16, 2016.
133. Franciscus A. A Brief History of Hepatitis C. HCSP Fact Sheet. March 2015. http://hcvadvocate.org/hepatitis/factsheets_pdf/Brief_History_HCV.pdf. Accessed February 16, 2016.
134. www.hepc.liverfoundation.org/treatment/the-basics-about-hepatitis-c-treatment/advances-in-medications/
135. www.hepatitiscnewdrugresearch.com/approved-treatments-for-hepatitis-c.html
136. American Cancer Society. Evolution of Cancer Treatments: Surgery. http://www.cancer.org/cancer/cancerbasics/thehistoryofcancer/the-history-of-cancer-cancer-treatment-surgery. Accessed February 16, 2016.
137. American Cancer Society. Evolution of Cancer Treatments: Chemotherapy. http://www.cancer.org/cancer/cancerbasics/thehistoryofcancer/the-history-of-cancer-cancer-treatment-chemo. Accessed February 16, 2016.
138. www.cancer.net/navigatin-cancer-care/how-cancer-treated/personalized-and-targeted-therapies/what-personalized-cancer-medicine
139. Schilsky RL. Nat. Rev. Drug. Discov. 2010;9(5):363-366.
140. Andre F, Ciccolini J, Spano J-P, et.al. Pharmacogenomics 2013;14(8):931-939.
141. American Cancer Society. Evolution of Cancer Treatments: Targeted therapy. http://www.cancer.org/cancer/cancerbasics/thehistoryofcancer/the-history-of-cancer-cancer-treatment-targeted-therapy. Accessed February 16, 2016.
142. ASCO Top 5 advances in modern oncology. #3 Advance: Targeted drug transforms treatment for rare leukemia, 2001. http://cancerprogress.net/top-5-advances-modern-oncology-3
143. ASCO Top 5 advances in modern oncology. #3 Advance: Targeted drug transforms treatment for rare leukemia, 2001. http://cancerprogress.net/top-5-advances-modern-oncology-3
144. American Diabetes Association. History of diabetes. http://www.diabetes.org/research-and-practice/student-resources/history-of-diabetes.html?referrer=https://www.google.com/. Accessed February 16, 2016.
145. American Diabetes Association. History of diabetes http://www.diabetes.org/research-and-practice/student-resources/history-of-diabetes.html?referrer=https://www.google.com/. Accessed February 16, 2016.
146. American Diabetes Association. http://www.diabetes.org/research-and-practice/student-resources/history-of-diabetes.html?referrer=https://www.google.com/. Accessed February 16, 2016.
147. Okada-Iwabu M, Yamauchi T, Iwabu M, et.al. Nature 2013;503(7477):493-499.
148. Stone E (1763) Phil Trans Royal Soc. London 53: 195-200
149. https://explorable.com/scientific-control-group
150. Eggert US. (2013) Nature Chemical Biology. 9:206-209.
151. Bhatt A. The evolution of clinical trial research: a history before and beyond James Lind. Perspect Clin Res. 2010;1(1):6-10
152. https://embryo.asu.edu/pages/us-regulatory-response-thalidomide-1950-2000
153. https://embryo.asu.edu/pages/us-regulatory-response-thalidomide-1950-2000
154. Arizona Center for Integrative Medicine. Inflammation: A common denominator of disease. June 26, 2013.
155. Sarker D, Fisher PB. Molecular mechanisms of aging-associated inflammation. Cancer Lett. 2006;236(1):13-23.
156. Public Release. Eureka Alert! AAAS. May 12, 2015. http://www.eurekalert.org/pub_releases/2015-05/uoc–dpu051215.php
157. Ni et al. A molecular level landscape of diet-gut microbiome interactions toward dietary interventions targeting bacterial genes. mBio. 2015;6(6):e01263-15.
158. Ni et al. A molecular level landscape of diet-gut microbiome interactions toward dietary interventions targeting bacterial genes. mBio. 2015;6(6):e01263-15.
159. Schreiner et al. The gut microbiome in health and disease. Curr Opin Gastroenterol. 2015;31(1):69-75.
160. Ni et al. A molecular level landscape of diet-gut microbiome interactions toward dietary interventions targeting bacterial genes. mBio. 2015;6(6):e01263-15
161. Cohen Y. Small molecules: the silent majority. http://www.xconomy.com.
162. Gautam A, Pan X. The changing model of big pharma: impact of key trends. Drug Discovery Today. Oct. 2015
163. http://www.roche.com/media/store/releases/med-cor-2015-11-12.htm
164. http://www.roche.com/media/store/releases/med-cor-2015-11-12.htm
165. https://www.astrazeneca.com/media-centre/press-releases/2015/AstraZeneca-continues-strategic-investment-in-China-to-accelerate-delivery-of-innovative-biologics-and-targeted-medicines-16122015.html
166. NIH National Human Genome Research Institute. https://www.genome.gov/20019523
167. NIH National Human Genome Research Institute. https://www.genome.gov/20019523
168. Li G, Diogo D, Wu D, et al. Human genetics in rheumatoid arthritis guides a high-throughput drug screen of the CD40 signalling pathway. PLOS Genetics. May 16 2013.
169. http://www.xconomy.com/boston/2013/02/14/the-holy-grail-of-drug-development-small-molecules-with-the-power-of-biologics/
170. http://www.xconomy.com/boston/2013/02/14/the-holy-grail-of-drug-development-small-molecules-with-the-power-of-biologics/
171. http://www.xconomy.com/boston/2013/02/14/the-holy-grail-of-drug-development-small-molecules-with-the-power-of-biologics/
172. http://ensembletx.com/fassino/wp-content/uploads/2015/11/PR08062013.pdf
173. HHMI News. 3D printer for small molecules opens access to customized chemistry. Mar. 12, 2015. https://www.hhmi.org/
174. HMI News. 3D printer for small molecules opens access to customized chemistry. Mar. 12, 2015. https://www.hhmi.org/
175. http://www.fiercepharma.com/special-reports/top-15-pharma-companies-2014-revenue
176. Gautam A, Pan X. The changing model of big pharma: impact of key trends. Drug Discovery Today. Oct. 2015.
177. Gautam A, Pan X. The changing model of big pharma: impact of key trends. Drug Discovery Today. Oct. 2015.
178. Gautam A, Pan X. The changing model of big pharma: impact of key trends. Drug Discovery Today. Oct. 2015.
179. Gautam A, Pan X. The changing model of big pharma: impact of key trends. Drug Discovery Today. Oct. 2015.
180. Price Waterhouse Coopers. From vision to decision Pharma 2020. www.pwc.com/pharma2020.
181. Gautam A, Pan X. The changing model of big pharma: impact of key trends. Drug Discovery Today. Oct. 2015.
182. Price Waterhouse Coopers. From vision to decision Pharma 2020. www.pwc.com/pharma2020. 2015
183. Price Waterhouse Coopers. From vision to decision Pharma 2020. www.pwc.com/pharma2020.
184. Gautam A, Pan X. The changing model of big pharma: impact of key trends. Drug Discovery Today. Oct. 2015.
185. Lilly receives FDA breakthough therapy designation for abemaciclib. http://lilly.mediaroom.com/index.php?s=9042&item=137472
186. New Entrants: The Healthcare Disrupters. http://www.pharmavoice.com/article/2015-11-nontraditional-players/